3-(4-(4-(5-butyl-4-(4-(4-chlorophenoxy)phenyl)thiazol-2-yl)piperidin-1-yl)buty1)-1-isopropyl-1H-indole-5-carbonitrile

ID: ALA5204858

Chembl Id: CHEMBL5204858

PubChem CID: 163216011

Max Phase: Preclinical

Molecular Formula: C40H45ClN4OS

Molecular Weight: 665.35

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCCc1sc(C2CCN(CCCCc3cn(C(C)C)c4ccc(C#N)cc34)CC2)nc1-c1ccc(Oc2ccc(Cl)cc2)cc1

Standard InChI:  InChI=1S/C40H45ClN4OS/c1-4-5-9-38-39(30-11-15-34(16-12-30)46-35-17-13-33(41)14-18-35)43-40(47-38)31-20-23-44(24-21-31)22-7-6-8-32-27-45(28(2)3)37-19-10-29(26-42)25-36(32)37/h10-19,25,27-28,31H,4-9,20-24H2,1-3H3

Standard InChI Key:  YZVCFFBGGZKTLI-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5204858

    ---

Associated Targets(Human)

AGER Tchem Advanced glycosylation end product-specific receptor (291 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A4 Tclin Serotonin transporter (12625 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 665.35Molecular Weight (Monoisotopic): 664.3003AlogP: 11.21#Rotatable Bonds: 13
Polar Surface Area: 54.08Molecular Species: BASEHBA: 6HBD:
#RO5 Violations: 2HBA (Lipinski): 5HBD (Lipinski): #RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 9.37CX LogP: 11.21CX LogD: 9.25
Aromatic Rings: 5Heavy Atoms: 47QED Weighted: 0.12Np Likeness Score: -1.21

References

1. Zhang C, Wang L, Xu Y, Huang Y, Huang J, Zhu J, Wang W, Li W, Sun A, Li X, Zhang H, Li J..  (2022)  Discovery of novel dual RAGE/SERT inhibitors for the potential treatment of the comorbidity of Alzheimer's disease and depression.,  236  [PMID:35430560] [10.1016/j.ejmech.2022.114347]

Source